Tarsus Pharmaceuticals Reports Fiscal Q3 Net Loss
Tarsus Pharmaceuticals reported a fiscal 2026 third-quarter net loss attributable to shareholders, down 1,095.37% year over year, and negative basic EPS.
Tarsus Pharmaceuticals reported a fiscal 2026 third-quarter net loss attributable to shareholders, down 1,095.37% year over year, and negative basic EPS.